A non-interventional study to evaluate the efficacy and safety ofeverolimus (EVE) + exemestane (EXE) in patients with HR+, HER2− advanced breast cancer progressing on/after prior endocrine therapy, in routine clinical practice

Trial Profile

A non-interventional study to evaluate the efficacy and safety ofeverolimus (EVE) + exemestane (EXE) in patients with HR+, HER2− advanced breast cancer progressing on/after prior endocrine therapy, in routine clinical practice

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 10 Dec 2016

At a glance

  • Drugs Everolimus (Primary) ; Exemestane (Primary)
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Acronyms STEPAUT
  • Most Recent Events

    • 07 Jun 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top